A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation?

Vivienne A Ezzat, Victor Lee, Syed Ahsan, Anthony W Chow, Oliver Segal, Edward Rowland, Martin D Lowe, Pier D Lambiase, Vivienne A Ezzat, Victor Lee, Syed Ahsan, Anthony W Chow, Oliver Segal, Edward Rowland, Martin D Lowe, Pier D Lambiase

Abstract

Implantable cardioverter defibrillator (ICD) implantation carries a significant risk of complications, however published estimates appear inconsistent. We aimed to present a contemporary systematic review using meta-analysis methods of ICD complications in randomised controlled trials (RCTs) and compare it to recent data from the largest international ICD registry, the US National Cardiovascular Data Registry (NCDR). PubMed was searched for any RCTs involving ICD implantation published 1999-2013; 18 were identified for analysis including 6433 patients, mean follow-up 3 months-5.6 years. Exclusion criteria were studies of children, hypertrophic cardiomyopathy, congenital heart disease, resynchronisation therapy and generator changes. Total pooled complication rate from the RCTs (excluding inappropriate shocks) was 9.1%, including displacement 3.1%, pneumothorax 1.1% and haematoma 1.2%. Infection rate was 1.5%.There were no predictors of complications but longer follow-up showed a trend to higher complication rates (p=0.07). In contrast, data from the NCDR ICD, reporting on 356 515 implants (2006-2010) showed a statistically significant threefold lower total major complication rate of 3.08% with lead displacement 1.02%, haematoma 0.86% and pneumothorax 0.44%. The overall ICD complication rate in our meta-analysis is 9.1% over 16 months. The ICD complication reported in the NCDR ICD registry is significantly lower despite a similar population. This may reflect under-reporting of complications in registries. Reporting of ICD complications in RCTs and registries is very variable and there is a need to standardise classification of complications internationally.

Keywords: QUALITY OF CARE AND OUTCOMES.

Figures

Figure 1
Figure 1
Complication rates in randomised controlled trials (RCTs) compared to registry.

References

    1. .
    1. Al-Khatib SM, Hellkamp A, Bardy GH et al. . Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA 2013;309:55–62. 10.1001/jama.2012.157182
    1. van Rees JB, de Bie MK, Thijssen J et al. . Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011;58:995–1000. 10.1016/j.jacc.2011.06.007
    1. Dodson JA, Reynolds MR, Bao H et al. . Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2014;63:788–96. 10.1016/j.jacc.2013.09.079
    1. Freeman JV, Wang Y, Curtis JP et al. . Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation 2012;125:57–64. 10.1161/CIRCULATIONAHA.111.046995
    1. Schinkel AF, Vriesendorp PA, Sijbrands EJ et al. . Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail 2012;5:552–9. 10.1161/CIRCHEARTFAILURE.112.969626
    1. Steinbeck G, Andresen D, Seidl K et al. . Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427–36. 10.1056/NEJMoa0901889
    1. Kron J, Herre J, Renfroe EG et al. . Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 2001;141:92–8. 10.1067/mhj.2001.111261
    1. Kremers MS, Hammill SC, Berul CI et al. . The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm 2013;10:e59–65. 10.1016/j.hrthm.2013.01.035
    1. Almendral J, Arribas F, Wolpert C et al. . Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace 2008;10:528–35. 10.1093/europace/eun072
    1. Kadish A, Dyer A, Daubert JP et al. . Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151–8. 10.1056/NEJMoa033088
    1. Hammill SC, Kremers MS, Stevenson LW et al. . Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm 2010;7:1340–5. 10.1016/j.hrthm.2010.07.015
    1. Lee DS, Krahn AD, Healey JS et al. . Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010;55:774–82. 10.1016/j.jacc.2009.11.029
    1. Uslan DZ, Gleva MJ, Warren DK et al. . Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE Registry. Pacing Clin Electrophysiol 2012;35:81–7. 10.1111/j.1540-8159.2011.03257.x
    1. Kirkfeldt RE, Johansen JB, Nohr EA et al. . Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35:1186–94. 10.1093/eurheartj/eht511
    1. Epstein AE, Dimarco JP, Ellenbogen KA et al. . ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:e1–62. 10.1016/j.hrthm.2008.04.014
    1. Tracy CM, Epstein AE, Darbar D et al. . 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2012;9:1737–53. 10.1016/j.hrthm.2012.08.021
    1. Zipes DP, Camm AJ, Borggrefe M et al. . ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746–837. 10.1093/europace/eul108
    1. Dickstein K, Vardas PE, Auricchio A et al. . 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677–87. 10.1093/eurheartj/ehq027
    1. Anderson KP. Estimates of implantable cardioverter-defibrillator complications: caveat emptor. Circulation 2009;119:1069–71. 10.1161/CIRCULATIONAHA.108.841452
    1. Brignole M. Are complications of implantable defibrillators under-estimated and benefits over-estimated? Europace 2009;11:1129–33. 10.1093/europace/eup174
    1. Brinker JA. Implantable cardioverter-defibrillator lead failure: how weak is the link? Nat Clin Pract Cardiovasc Med 2008;5:758–9. 10.1038/ncpcardio1367
    1. Calkins H, Ramza BM, Brinker J et al. . Prospective randomized comparison of the safety and effectiveness of placement of endocardial pacemaker and defibrillator leads using the extrathoracic subclavian vein guided by contrast venography versus the cephalic approach. Pacing Clin Electrophysiol 2001;24(4 Pt 1):456–64. 10.1046/j.1460-9592.2001.00456.x
    1. Deisenhofer I, Kolb C, Ndrepepa G et al. . Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol 2001;12:134–42. 10.1046/j.1540-8167.2001.00134.x
    1. Bänsch D, Antz M, Boczor S et al. . Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453–8. 10.1161/
    1. Moss AJ, Zareba W, Hall WJ et al. . Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83. 10.1056/NEJMoa013474
    1. Vollmann D, Ahern T, Gerritse B et al. . Worldwide evaluation of a defibrillation lead with a small geometric electrode surface for high-impedance pacing. Am Heart J 2003;146:1066–70. 10.1016/S0002-8703(03)00411-3
    1. Bänsch D, Steffgen F, Grönefeld G et al. . The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation 2004;110:1022–9. 10.1161/01.CIR.0000140259.16185.7D
    1. Bokhari F, Newman D, Greene M et al. . Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004;110: 112–16. 10.1161/01.CIR.0000134957.51747.6E
    1. Hohnloser SH, Kuck KH, Dorian P et al. . Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481–8. 10.1056/NEJMoa041489
    1. Bänsch D, Kottkamp H, Grönefeld G et al. . The quick-implantable-defibrillator trial. Europace 2007;9:1144–50. 10.1093/europace/eum126
    1. Reddy VY, Reynolds MR, Neuzil P et al. . Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–65. 10.1056/NEJMoa065457
    1. Russo AM, Day JD, Stolen K et al. . Implantable cardioverter defibrillators: do women fare worse than men? Gender comparison in the INTRINSIC RV trial. J Cardiovasc Electrophysiol 2009;20:973–8. 10.1111/j.1540-8167.2009.01489.x
    1. Kuck KH, Schaumann A, Eckardt L et al. . Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40. 10.1016/S0140-6736(09)61755-4
    1. Varma N, Epstein AE, Irimpen A et al. . Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010;122:325–32. 10.1161/CIRCULATIONAHA.110.937409
    1. Cheng A, Nazarian S, Brinker JA et al. . Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm 2011;8:536–40. 10.1016/j.hrthm.2010.12.016

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다